Wet Age-related Macular Degeneration Clinical Trial
Official title:
Phase I Clinical Trial of Recombinant Anti-VEGF Human Monoclonal Antibody in the Treatment of Wet Age-related Macular Degeneration
Multicenter study to evaluate the safety and tolerability in patients with wet Age-related macular degeneration (wAMD) treated with intravitreal recombinant humanized anti-VEGF monoclonal antibody
Status | Recruiting |
Enrollment | 67 |
Est. completion date | September 15, 2021 |
Est. primary completion date | March 15, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 45 Years to 80 Years |
Eligibility |
Inclusion Criteria: 1. Sign informed consent form and willing to be visited at the time specified in the trial; 2. Age =45 years and age = 80 years; 3. The study eye must meet the following criteria: - Diagnosis of wAMD; - The presence of an primary or recurrent active choroidal neovascular (CNV) lesions in subfovea and para-fovea secondary to AMD; - Total area of all types of lesions =30mm2 (12 optic disc areas) - Best EDTRS letter score between 19 and 78(Snellen equivalent of 20/400 to 20/32); - No optometric media opacity and pupil shrinkage. 4. Best EDTRS letter score =19 (Snellen equivalent of 20/400 or better) in the fellow eyes. Exclusion Criteria: Any of the following eye conditions: 1. Any eye has active ocular infections (e.g.,blepharitis, keratitis, scleritis, conjunctivitis); 2. History of vitreous hemorrhage in the study eye within 2 months before screening; 3. scarring, fibrosis, or atrophy below with fovea in the study eye; 4. Received any drug treatment for CNV within 120 days prior to screening; 5. History of any following surgery in the study eye (e.g. PDT, macular transposition, Glaucoma filtration, subfoveal photocoagulation, vitrectomy and transpupular hyperthermia, and other surgery at the submacular or others for AMD) within 3 months before screening; 6. CNV in the study eye associated with other ocular diseases such as pathologic myopia, eye trauma, etc 7. History or present of uncontrolled glaucoma, history of glaucoma filtering surgery in the study eye; 8. Subretinal hemorrhage in the study eye, and the bleeding area = 50% area of the total lesion; 9. History of rhegmatogenous retinal detachment or macular hole retinal detachment (stage 3 or 4) , retinal detachment, retinal pigment epithelium tear or macular area traction and macular area preretinal membrane and PCV in the study eye; 10. The study eye has no lens( except intraocular lens) or posterior capsular rupture of the lens; Any of the following general condition are present: 11. Medicines with toxicity to the lens are being used or may be used during the study period; 12. History of allergy to fluorescein sodium and allergies to protein products for treatment or diagnosis, history of allergy to more than two drugs and/or non-drug factors, or suffering from allergic diseases now. 13. History of surgery within 1 months before screening; and/or unhealed wounds, ulcers or fractures currently; 14. Suffering from systemic infections and requiring oral, intramuscular or intravenous medication; 15. History of stroke, myocardial infarction within 6 months before screening; 16. Active diffuse intravascular coagulation and obvious bleeding tendency within 3 months before screening; 17. Systemic immune diseases; 18. Uncontrolled blood pressure control ; 19. Diabetic patients with uncontrolled blood sugar; 20. Any uncontrolled clinical problems (such as severe mental, neurological, cardiovascular, respiratory and other systemic diseases and malignant tumours); Any of the following laboratory tests abnormalities(23-25): 21. Renal function impairment (Cr is 1.5 times higher than the upper limit of normal values in the local laboratory) Liver dysfunction (ALT or AST is 2 times higher than the upper limit of normal value in the local laboratory). 22. Abnormal coagulation function (prothrombin time >= the upper limit of normal value for 3 seconds) and activated partial thromboplastin time >= the upper limit of normal value for 10 seconds); Patients with childbearing age with any of the following conditions: 23. Those who do not use effective contraceptive measures; The following are not excluded: 24. Pregnancy and lactation women (pregnancy is defined as urinary pregnancy test positive in this study); Any other conditions: 25. Participation in any other drug clinical trials (except vitamins and minerals) in the past 1 month before screening ; 26. Researchers think it needs to be ruled out. |
Country | Name | City | State |
---|---|---|---|
China | BeiJing Hospital | Beijing |
Lead Sponsor | Collaborator |
---|---|
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | DLT | Incidence of dose-limiting toxicities up to the Day 14 visit | From Day 0 up to Day 14 | |
Primary | MTD | Maximum tolerated dose | From Day 0 up to Day 56/112. | |
Secondary | Pharmacokinetic (PK) profile | Study the change of 601 drug concentration in the blood with time by mathematical principles and methods | From Day 0 up to 56/112 days | |
Secondary | Cmax | The maximum blood concentration after 601 drug enters the bloodstream | From Day 0 up to 56/112 days | |
Secondary | t1/2 | The half-life of drug 601, the time required for the terminal phase 601 drug concentration to drop by half | From Day 0 up to 56/112 days | |
Secondary | AUC | Area under the concentration-time curve, reflect the characteristics of the exposure of 601 drug in the body. | From Day 0 up to 56/112 days | |
Secondary | Vd | The proportional constant between the amount of 601 drug in the body and the blood concentration when the 601 drug achieves the dynamic balance in the body. | From Day 0 up to 56/112 days | |
Secondary | CL | Clearance rate of drug 601 from the central ventricle. | From Day 0 up to 56/112 days | |
Secondary | MRT | The average length of time that the 601 drug stays in the body. | From Day 0 up to 56/112 days | |
Secondary | ?z | the ratio of the amount of elimination of 601 drug from the body per unit time to the total amount in the body | From Day 0 up to 56/112 days | |
Secondary | Biomarker | Detection of VEGF concentration. | From Day 0 up to 56/112 days | |
Secondary | Immunogenicity | Development of Anti-drug antibodies (ADA) after IVT injection of 601 | From Day 0 up to 56/112 days | |
Secondary | CRT | Changes in central retina thickness (CRT) at all time points compared to the baseline | From Day 0 up to 56/364 days | |
Secondary | diseased region | Changes in the diseased region at all time points compared to the baseline | From Day 0 up to 56/364 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00138632 -
Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
Terminated |
NCT04594681 -
A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration
|
Phase 1 | |
Completed |
NCT03585556 -
AAVCAGsCD59 for the Treatment of Wet AMD
|
Phase 1 | |
Completed |
NCT03362190 -
ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)
|
Phase 2 | |
Not yet recruiting |
NCT04564937 -
The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04504123 -
MMP-9 Inhibition for Recalcitrant Wet AMD
|
Phase 2 | |
Terminated |
NCT02005133 -
A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics
|
N/A | |
Completed |
NCT01016873 -
INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
|
Phase 2 | |
Completed |
NCT03748784 -
ADVM-022 Intravitreal Gene Therapy for Wet AMD
|
Phase 1 | |
Completed |
NCT04685369 -
Effectiveness of Anti-VEGF Treatments in Wet AMD in Active Smokers
|
||
Enrolling by invitation |
NCT04932980 -
Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD
|
N/A | |
Recruiting |
NCT05297292 -
A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD
|
Phase 2/Phase 3 | |
Completed |
NCT03939767 -
Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease
|
||
Completed |
NCT03066258 -
Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial
|
Phase 1/Phase 2 | |
Terminated |
NCT01086761 -
Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration
|
Phase 1 | |
Recruiting |
NCT05727397 -
Efficacy and Safety of RC28-E Versus Aflibercept
|
Phase 3 | |
Completed |
NCT04884399 -
Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD
|
Phase 1 | |
Completed |
NCT04964089 -
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
|
Phase 3 | |
Withdrawn |
NCT01339949 -
Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)
|
N/A | |
Terminated |
NCT00139282 -
A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for "Wet" Age-Related Macular Degeneration
|
Phase 3 |